Literature DB >> 7606887

Antitumor effects of liposomal IL1 alpha and TNF alpha against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice.

M Saito1, D Fan, L B Lachman.   

Abstract

Interleukin 1 alpha (IL1 alpha) and tumor necrosis factor alpha (TNF alpha) have been successfully incorporated into specific phosphatidylcholine (PC) and phosphatidylserine (PS) multilamellar vesicle (MLV) liposomes by modifying the concentration of calcium ion and pH of the encapsulation buffer. Under these conditions, some of the cytokines may attach to the exterior surface of the MLV and therefore be readily accessible to target cells for receptor binding and signal transduction. These cytokine-associated liposomes are stable for up to 2 weeks in serum-free buffer, and leakage of cytokines into medium containing 10% fetal bovine serum was about 50% at the end of a 3-day incubation period at 37 degrees C. The biological activities mediated by liposomal IL1 alpha and TNF alpha were specific: the stimulation of thymidine uptake in T-helper D10 lymphocytes and the cytolysis of TNF alpha-sensitive L929 target cells could be blocked by specific neutralizing antibodies in a dose-dependent fashion. When administered intravenously into C57BL/6 mice bearing the syngeneic B16F10 murine melanoma cells, dual entrapment of liposomal IL1 alpha and TNF alpha significantly reduced the number of metastatic tumor nodules in the lungs and prolonged the life span of the animals. Thus, liposomal IL1 alpha and TNF alpha displayed significant in vivo antitumor activity against the IL1 alpha- and TNF alpha-resistant B16F10 metastatic murine melanoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606887     DOI: 10.1007/BF00133480

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  57 in total

1.  Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.

Authors:  M Maeda; R D Knowles; E S Kleinerman
Journal:  Cancer Commun       Date:  1991

2.  Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 1 beta by interleukin 2.

Authors:  E J Kovacs; S K Beckner; D L Longo; L Varesio; H A Young
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

3.  Clustering of lecithin molecules in phosphatidylserine membranes induced by calcium ion binding to phosphatidylserine.

Authors:  S Ohnishi; T Ito
Journal:  Biochem Biophys Res Commun       Date:  1973-03-05       Impact factor: 3.575

4.  Activated human blood monocytes trigger the antitumor activity of blood polymorphonuclear cells.

Authors:  I J Fidler; A Nii; J Y Tsao; S Davis; E S Kleinerman
Journal:  Lymphokine Res       Date:  1989

5.  Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects.

Authors:  J Ferluga; H U Schorlemmer; L C Baptista; A C Allison
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

6.  Antiproliferative activity of liposome-encapsulated transforming growth factor-beta against MDA-MB-435 human breast carcinoma cells.

Authors:  D Fan; J Price; H Schackert; C Seid; C Wilmanns; S Chakrabarty; I J Fidler
Journal:  Cancer Commun       Date:  1989

7.  Role of interleukin 1 in promoting human monocyte-mediated tumor cytotoxicity.

Authors:  K Onozaki; K Matsushima; E S Kleinerman; T Saito; J J Oppenheim
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

8.  Effect of interleukin-1-beta on metastasis formation in different tumor systems.

Authors:  M R Bani; A Garofalo; E Scanziani; R Giavazzi
Journal:  J Natl Cancer Inst       Date:  1991-01-16       Impact factor: 13.506

9.  Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin.

Authors:  K Mace; E Mayhew; E Mihich; M J Ehrke
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

10.  Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis.

Authors:  D Lovett; B Kozan; M Hadam; K Resch; D Gemsa
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

View more
  4 in total

1.  Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals.

Authors:  J Huang; P Woods; D Normolle; J P Goff; P V Benos; C J Stehle; R A Steinman
Journal:  Breast Cancer Res Treat       Date:  2016-11-16       Impact factor: 4.872

Review 2.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

3.  In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.

Authors:  Xingyi Guo; Yaomin Xu; Zhongming Zhao
Journal:  Mol Cancer       Date:  2015-03-14       Impact factor: 27.401

4.  In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors.

Authors:  Y Tsutsumi; S Tsunoda; Y Kaneda; H Kamada; T Kihira; S Nakagawa; Y Yamamoto; Y Horisawa; T Mayumi
Journal:  Jpn J Cancer Res       Date:  1996-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.